Telomir Pharmaceuticals Inc
TELO1.845USD
+0.085+4.83%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
54.91MCap. mercado
PérdidaP/E TTM
Más Datos de Telomir Pharmaceuticals Inc Compañía
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, thereby promoting longevity in humans and canine animals by treating age-related conditions. TELOMIR-1 is undergoing studies to provide a therapeutic intervention against contracting a number of degenerative and age-related diseases. Its Telomir-1, is being investigated for its potential to address a range of conditions, including Type 2 diabetes, Wilson’s disease, progeria, Alzheimer’s disease, and cancer. The Company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life. It is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal.
Información de la empresa
Símbolo de cotizaciónTELO
Nombre de la empresaTelomir Pharmaceuticals Inc
Fecha de salida a bolsaFeb 09, 2024
Director ejecutivoMr. Erez Aminov
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 09
Dirección900 West Platt Street, Suite 200
CiudadTAMPA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33606
Teléfono18138642562
Sitio Webhttps://telomirpharma.com/
Símbolo de cotizaciónTELO
Fecha de salida a bolsaFeb 09, 2024
Director ejecutivoMr. Erez Aminov
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Independent Director
Independent Director
487.81K
--
Dr. Matthew P. Del Giudice
Dr. Matthew P. Del Giudice
Director
Director
--
--
Mr. Ned Macpherson
Mr. Ned Macpherson
Director
Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Independent Director
Independent Director
487.81K
--
Dr. Matthew P. Del Giudice
Dr. Matthew P. Del Giudice
Director
Director
--
--
Mr. Ned Macpherson
Mr. Ned Macpherson
Director
Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bay Shore Trust
22.62%
McNulty (Brian Patrick)
6.31%
The Vanguard Group, Inc.
4.23%
BlackRock Institutional Trust Company, N.A.
3.76%
Aminov (Erez)
3.39%
Other
59.69%
Accionistas
Accionistas
Proporción
Bay Shore Trust
22.62%
McNulty (Brian Patrick)
6.31%
The Vanguard Group, Inc.
4.23%
BlackRock Institutional Trust Company, N.A.
3.76%
Aminov (Erez)
3.39%
Other
59.69%
Tipos de accionistas
Accionistas
Proporción
Corporation
22.62%
Individual Investor
11.55%
Investment Advisor
9.09%
Investment Advisor/Hedge Fund
2.98%
Research Firm
0.29%
Pension Fund
0.07%
Bank and Trust
0.07%
Other
53.33%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
88
13.89M
46.68%
+947.95K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bay Shore Trust
6.73M
22.62%
-89.00K
-1.30%
Dec 31, 2024
McNulty (Brian Patrick)
1.88M
6.31%
-49.00K
-2.54%
Dec 31, 2024
The Vanguard Group, Inc.
1.26M
4.23%
-10.56K
-0.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.12M
3.76%
+119.04K
+11.91%
Mar 31, 2025
Aminov (Erez)
1.01M
3.39%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.64%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
429.25K
1.44%
+15.57K
+3.77%
Mar 31, 2025
Northern Trust Investments, Inc.
151.10K
0.51%
-525.00
-0.35%
Mar 31, 2025
State Street Global Advisors (US)
125.67K
0.42%
+9.88K
+8.53%
Mar 31, 2025
Suncoast Equity Management, LLC.
51.19K
0.17%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
